Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgeryEvan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian CancerYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Plos One|May 11, 2026
Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naïve individuals associated with Omicron breakthrough infectionsYiwen Liu, Eric Lu, Katherine D Ellingson, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|November 14, 2024
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsMalek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, et al.
Journal for Immunotherapy of Cancer|June 30, 2025
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohortSandip Pravin Patel, Jillian Fisher, Young Kwang Chae, et al.
Clinical Genitourinary Cancer|December 8, 2022
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder, et al.
European Journal of Gastroenterology & Hepatology|January 12, 2026
Risk factors and clinical course of inflammatory bowel disease in patients receiving cancer therapyCristina Natha, Carolina Colli Cruz, Varun Vemulapalli, et al.
Cancer Discovery|April 29, 2017
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP InhibitorsDavid Quigley, Joshi J Alumkal, Alexander W Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Pageof 15